Vibrating mattresses combined with blood pressure medication help clear waste proteins from the brains of healthy human volunteers, according to a recent Finnish study.
Researchers at the University of Oulu tested the method on 29 participants aged 27 to 61, administering two doses of a blood pressure-lowering drug before placing them on a vibrating bed for just over 30 minutes.
Following the session, blood tests revealed increased levels of two beta-amiloid protein types linked to Alzheimer’s disease. The procedure also elevated levels of the GFAP protein, which supports and protects neurons. Investigators interpret these blood concentration spikes as evidence that waste products successfully crossed from brain tissue into the circulatory system.
However, the concentration of tau protein, which correlates strongly with disease progression, remained unchanged. The intervention produced stronger effects in older participants and those who experienced greater blood pressure drops. Imaging scans confirmed that waste removal occurred primarily through veins in the back of the brain, matching the gravitational flow expected for individuals lying flat on their backs.
The experimental setup mimics physiological changes that naturally occur during deep sleep. Brains typically clear metabolic waste during rest cycles when cerebral blood pressure drops and vessel walls pulse slowly. Age degrades this natural clearance system, while neurodegenerative disorders accelerate harmful protein accumulation.
“The results suggest that harmful proteins were eliminated from the brain more efficiently than usual,” Johanna Tuunanen, a biomedical engineer at the University of Oulu, told Science Alert.
The intervention successfully stimulated the brain’s waste clearance pathways without requiring invasive procedures. Investigators hope that boosting this natural purging process in healthy aging adults will eventually prevent or delay the onset of dementia. The current experiment does not prove that the mattress prevents Alzheimer’s or improves memory, as the participants showed no signs of cognitive decline, and researchers did not directly measure intracranial protein levels.
Twenty-nine healthy volunteers aged 27 to 61 took part in the trial. None of the participants suffered from dementia or cognitive impairment.
Blood tests showed elevated levels of two beta-amiloid protein types and the astrocyte-associated GFAP protein. The concentration of tau protein showed no measurable change after the vibration session.
The University of Oulu team plans to test the vibrating mattress method over longer time periods. Subsequent trials will focus on individuals who already exhibit early memory impairment symptoms, building on prior animal studies involving mice.
Keep reading